Study 39 of 39Orforglipron (LY-3502970) literatureAnnals of internal medicineTop journal

In T2D inadequately controlled with metformin, orforglipron reduced HbA<sub>1c</sub> more than dapagliflozin at 40 wk.

The abstract does not provide sufficient data to draw conclusions about the effectiveness of orforglipron compared to dapagliflozin in managing HbA1c levels.

Read at Annals of internal medicine Add to compare

Where it sits

this study against the rest of the orforglipron (ly-3502970) corpus

Preclinical · this one

Observational

Open-label

Randomised

Reviews

Summary and findings

In a population with type 2 diabetes inadequately controlled with metformin, orforglipron was compared to dapagliflozin over 40 weeks. The study aimed to measure the reduction in HbA1c levels. Specific numeric outcomes were not reported in the abstract.

How much of this paper we could read: title only (0.20). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →

Abstract

The authors’ words, as Annals of internal medicine supplied them

<h4>Clinical impact ratings</h4>GIM/FP/GP: [Formula: see text] Endocrinology: [Formula: see text].

Background

This study addresses the efficacy of orforglipron in patients with type 2 diabetes who are not adequately controlled with metformin. Previous research has established the role of SGLT2 inhibitors like dapagliflozin in managing blood glucose levels. Understanding the comparative effectiveness of orforglipron is important for treatment options in this patient population.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Key findings

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the Orforglipron (LY-3502970) corpus

AEfficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial.The lancet. Diabetes & endocrinology · 2026 · Mean percentage change in bodyweight was -5.9% with orforglipron 6 mg, -8.7% with 12 mg, and -7.9% with 36 mg, compared with -0.6% with placebo (all p<0.0001).Human AEfficacy and safety of orforglipron in adults with body mass index of 27 to less than 30 kg/m<sup>2</sup> and adiposity-related complications: A post hoc analysis of the ATTAIN-1 trial.Obesity pillars · 2026 · n=260 · At Week 72, orforglipron 17.2 mg was associated with a mean percent body weight reduction of -13.5% versus placebo at -0.3%, nominal p < 0.001.Human DOrforglipron for Type 2 Diabetes and Pancreatic Risk Assessment.JAMA · 2026—DOrforglipron for Type 2 Diabetes and Pancreatic Risk Assessment-Reply.JAMA · 2026—DEstablishing cardiovascular safety of the small-molecule GLP-1 receptor agonist orforglipron in type 2 diabetes.Lancet (London, England) · 2026—AQualitative Exit Interviews to Characterize the Positive Treatment Experiences of Patients in the Phase III Trial of Orforglipron Versus Oral Semaglutide for the Treatment of Type 2 Diabetes.The patient · 2023 · n=60 · Patients reduced glycated hemoglobin by 1.6% (SD = 1.3) from a baseline of 8.3%.Human